Stevens Jennifer 4

What Happened
Jennifer Stevens, Chief Regulatory Officer of TriSalus Life Sciences (TLSI), reported three open-market sales in March 2026 totaling 3,530 shares for about $14,510. The sales were: 1,204 shares on 2026-03-11 at $4.13 ($4,973), 1,552 shares on 2026-03-12 at $4.09 ($6,348), and 774 shares on 2026-03-16 at $4.12 ($3,189). Per the filing footnote, these disposals were to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units (RSUs) and were not discretionary sales.

Key Details

• Transaction dates and prices:
  • 2026-03-11: Sold 1,204 shares @ $4.13 — $4,973
  • 2026-03-12: Sold 1,552 shares @ $4.09 — $6,348
  • 2026-03-16: Sold 774 shares @ $4.12 — $3,189
• Total sold: 3,530 shares for ~$14,510.
• Shares owned after the transactions: not specified in the provided filing.
• Footnote: F1 — Shares were sold to satisfy tax withholding on vested RSUs; transaction was not a discretionary sale by the reporting person.
• Filing: Form 4 filed on 2026-03-20 reporting the March 11–16 transactions. The filing itself does not include a late-filing flag in the summary provided here.

Context
Sales to cover tax withholding on RSU vesting are routine and typically do not signal a change in an insider’s view of the company. Retail investors should note this was a tax-related disposition (coded F) rather than an active, discretionary sell decision (which can carry different informational weight).